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Abstract
Background & Aims—Little is known about the diagnostic utility of the eosinophilic 
esophagitis (EoE) endoscopic reference score (EREFS), and how scores change in response to 
treatment. We investigated the operating characteristics of the EREFS in diagnosis of EoE, how 
the score changes with treatment, and ways to optimize scoring system.
Methods—We performed a prospective study of adults undergoing outpatient upper endoscopy 
from August 2011 through December 2013 at the North Carolina School of Medicine. Incident 
cases of EoE were diagnosed per consensus guidelines and were treated with topical steroids or 
dietary elimination (n=67); 144 subjects without EoE were included as controls. EREFS scores 
were compared between cases and controls. For EoE cases, scores were compared before and after 
treatment. Area under the receiver operator characteristic curve (AUC) analysis was used to 
determine diagnostic utility of the EREFS system. An iterative analysis was performed to 
determine optimal EREFS scoring weights.
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Results—The mean total EREFS score was 3.88 for EoE cases and 0.42 for controls (P>.001); 
the score identified subjects with EoE with an AUC of 0.934. After treatment of EoE cases, the 
mean score decreased from 3.88 to 2.01 (P>.001). This change was more prominent for patients 
with a histologic response (reduction to <15 eos/hpf), compared with non-responders; post-
treatment scores were 0.45 for responders vs 3.24 for non-responders (P<.001). A weighted 
scoring system that doubled exudates, rings, and edema scores maximized the responsiveness of 
the total EREFS score.
Conclusions—The EREFS classification system identifies patients with EoE an AUC of 0.934; 
the score decreases with treatment, and histologic responders have significantly lower scores than 
non-responders. This system can therefore be used to identify individuals with EoE and used as an 
endoscopic outcome measure to follow their response to treatment.
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Introduction
Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory clinicopathologic 
disease defined by symptoms of esophageal dysfunction and esophageal eosinophilia.1, 2 
EoE is frequently encountered in the endoscopy suite,3–5 but its multiple characteristic 
endoscopic signs including esophageal rings, strictures, narrowing, linear furrows, white 
plaques or exudates, decreased vascularity or edema, and fragile or “crêpe-paper” mucosa,6 
are not currently part of the EoE diagnostic criteria.1, 2 This is largely because there has only 
been fair agreement between physicians in assessing the features,7 and individual features 
have not been shown to be either sensitive or specific enough to support diagnosis.8
The recent proposal of the EoE Endoscopic Reference Score (EREFS) by Hirano and 
colleagues allows for consistency in the description, recognition, and reporting of findings.9 
After using a standard atlas illustrating this classification system, they showed good 
agreement between physicians in assessing exudates, rings, edema, furrows, and strictures. 
This agreement has now been shown in an independent population,10 and the ERFES has 
been recommended for use by clinicians to standardize reporting.11 Additionally, this 
system may be able to help identify inflammatory versus fibrostenotic features of EoE.12 
However, it is still unknown whether EREFS has diagnostic utility for EoE, if the measure is 
responsive to treatment, and if so, what the best scoring approach would be.
The aims of this study were to 1) describe the range of EREFS findings in a large set of EoE 
cases and non-EoE controls; 2) determine diagnostic operating characteristics of EREFS for 
EoE; 3) determine whether the EREFS score was responsive to treatment in EoE cases; and 
4) determine the optimal scoring system.
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Methods
Study design, case definitions, and clinical data
We performed an analysis of a prospective cohort study of patients enrolled from August, 
2011 (after implementation of the EREFS system after its first report13) through December, 
2013. Details of this parent protocol have been reported previously.14–16 In brief, 
consecutive patients undergoing outpatient endoscopy were recruited if they were 18 years 
or older and had symptoms of esophageal dysfunction (ie dysphagia, food impaction, 
heartburn, reflux, or chest pain). There was a mix of open-access endoscopy and endoscopy 
performed by the patient’s physician. The study coordinator screened the schedule for every 
upper endoscopy and then approached patients to determine eligibility. Exclusion criteria 
were: known diagnosis of either EoE or of a non-EoE eosinophilic gastrointestinal disorder 
(EGID); known esophageal cancer; prior esophageal surgery; GI bleeding; anticoagulation; 
known esophageal varices; medical instability or multiple comorbidities precluding 
enrollment in the clinical opinion of the endoscopist; and inability to read or understand the 
consent form. This study was approved by the UNC Institutional Review Board. Subjects 
provided informed consent prior to enrollment and endoscopy.
Incident EoE cases were diagnosed per consensus guidelines.1, 2 They were required to have 
a typical symptom of esophageal dysfunction, an esophageal biopsy with at least 15 
eosinophils per high-power field (eos/hpf) after an 8 week trial of a proton-pump inhibitor 
(PPI; 20–40 mg twice daily of any of the available agents, prescribed at the discretion of the 
clinician), and other causes of esophageal eosinophilia excluded. Non-EoE controls were 
subjects who, after endoscopy and biopsy, did not meet clinical and histologic criteria for 
EoE. Of note, patients with PPI-responsive esophageal eosinophilia were not included in this 
study.
Demographics, symptoms, and atopic conditions were recorded using standardized case 
report forms and a prospectively administered patient questionnaire. These data were 
recorded prior to the endoscopy and prior to knowing biopsy results and final case/control 
determination. Esophageal biopsies for research use were obtained (two from the proximal, 
one from the mid, and two from the distal esophagus) to maximize sensitivity for detecting 
an eosinophilic infiltrate.17, 18 To exclude concomitant eosinophilic gastroenteritis, gastric 
and duodenal biopsies were also collected. To quantify the maximum esophageal eosinophil 
density (eosinophils/mm2), slides were masked to case/control status, digitized, and 
eosinophil density was calculated using our previously validated methodology.19 This 
density was converted to an eosinophil count (eosinophils per high power field; eos/hpf) 
using a hpf size of 0.24 mm2, the most commonly reported field size in the literature,20 in 
order to compare results to prior studies.
Endoscopic data and the EREFS classification
During the baseline endoscopy, the study coordinator used a standardized case report form 
to prospectively record endoscopic findings and apply the EREFS classification system;9 the 
score was never calculated retrospectively based on captured images. As these were 
standard-of-care procedures, endoscopists were not blinded to the clinical details, including 
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whether the exam was to assess treatment response. Exudates were recorded as absent 
(grade 0), mild (covering <10% of the esophageal mucosa; grade 1), or severe (involving 
≥10% of the esophageal mucosa; grade 2). Rings were recorded as absent (grade 0), mild 
(circumferential ridges; grade 1), moderate (distinct rings that did not impair passage of a 
standard adult upper endoscope; grade 2), of severe (distinct rings that did not allow a 
standard adult upper endoscope to pass; grade 3). Edema was recorded as absent (grade 0) or 
present (loss of vascular markings; grade 1). Furrows were recorded as absent (grade 0), 
mild (present but without visible depth; grade 1), or severe (visible depth or mucosal 
indentation; grade 2). Strictures were recorded as absent (grade 0) or present (grade 1), and 
if present, the inner diameter of the stricture was estimated by the endoscopist prior to 
dilation. Fifteen endoscopists performed study procedures, but approximately three-quarters 
of exams were performed by the first author (ESD). An overview of the EREFS 
classification was provided, an image atlas was available, and the coordinator also provided 
the classification during the endoscopic examination to ensure that all endoscopists had 
access to the same knowledge base.
Treatment and follow-up
After identification, the EoE cases enrolled in this study were treated by their 
gastroenterologist as clinically indicated. Treatment options were either topical 
corticosteroids (either oral viscous budesonide 1 mg twice daily or fluticasone from a multi-
dose inhaler, 880 mcg twice daily) for 8 weeks,21–23 or dietary therapy with the six-food 
elimination diet (avoidance of dairy, wheat, egg, soy, nuts, and seafood) for 6 weeks.24, 25 
At the end of either treatment period, repeat upper endoscopy was performed, the full set of 
EREFS findings were again recorded, a follow-up set of esophageal biopsies were obtained, 
and histologic assessments were repeated. Response to treatment was defined histologically 
as a maximum eosinophil count of <15 eos/hpf.26
Statistical analysis
The features of the EoE cases and non-EoE controls were summarized using descriptive 
statistics. To assess the EREFS, we constructed several scores. First, individual features 
were scored by simply summing the severity grade; for example the score for exudates could 
range from 0 to 2, and the score for rings could range from 0 to 3. Second, a total EREFS 
score was creating by summing the grades for all five of the findings (this could range from 
0 to 9). Third, inflammatory and fibrostenotic subscores were generated. The inflammatory 
score contained the sum of the exudate, edema, and furrows scores (this could range from 0 
to 5), and the fibrostenotic score contained the sum of the rings and stricture scores (this 
could range from 0 to 4). For cases and controls, means were compared with a two-sample t-
test, and proportions were compared with chi-square. To compare baseline and follow-up 
EREFS scores among EoE cases and assess the responsiveness of the system, paired t-tests 
were used for continuous variables and chi-square was used for categorical variables. This 
analysis was repeated after stratifying by baseline esophageal dilation status. We also 
compared the EREFS features of EoE cases who were histologic responders (<15 eos/hpf) to 
those who were not (≥15 eos/hpf).
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In order to investigate the diagnostic utility of the EREFS to predict EoE case status (using 
the consensus diagnostic guidelines as the gold standard), we calculated the area under the 
receiver operator characteristic (ROC) curve (AUC). We then determined the EREFS score 
cut-point that would provide optimal sensitivity and specificity. We also evaluated the 
ability of both the baseline and follow-up EREFS scores to predict histologic treatment 
response, again utilizing ROC analysis. Finally, we examined various scoring paradigms to 
optimize the strength of association between change in EREFS score and either change in 
eosinophil count as a continuous variable or with a response threshold of 15 eosinophils per 
high power field. For each EREFS findings we assigned integer weights that varied from 
one to ten. For all possible combinations of these weights for all findings, we calculated 
weighted EREFS scores. The change before and after treatment in the weighted EREFS 
score was compared to the change in eosinophil counts on the basis of Pearson correlation 
coefficients for the continuous outcome and odds ratios for the threshold outcome. Strength 
of these associations was plotted as the mean of simulations for each finding. We then 
compared the best-performing weights, as measured by the change (the delta) between the 
pre- and post-treatment weights, to the unweighted EREFS score using ROC analysis. 
Analyses were performed with Stata (version 9.2; StataCorp; College Station, TX) and SAS 
(version 9.4; SAS Institute; Cary, NC).
Results
Range of EREFS findings and diagnostic utility in cases and controls
There were 67 EoE cases and 144 non-EoE controls included in this study (Table 1). When 
the EREFS classification was used to compare cases at baseline to controls, there were 
multiple highly significant differences between the groups (Table 2). Accordingly, the total 
EREFS score was 3.88 for EoE cases and 0.42 for controls (p < 0.001), with similar 
differences for the inflammatory and fibrostenotic sub-scores (Table 2).
On ROC analysis, a model that contained all five components of the EREFS system as 
categorical variables had an AUC of 0.946, indicating an excellent ability to predict EoE 
case status based on endoscopic findings alone. A model using the total EREFS score had an 
AUC of 0.934. For this model, a score of 2.0 or greater optimized diagnostic utility, with a 
sensitivity of 88%, specificity of 92%, positive predictive value (PPV) of 84%, negative 
predictive value (NPV) of 94%, and accuracy of 91%. Interestingly, the majority of this 
predictive ability was in the inflammatory component. The inflammatory score had an AUC 
of 0.936, whereas the fibrostenotic score had an AUC of 0.825, primarily owing to the high 
prevalence of strictures in the control group.
Responsiveness of the EREFS classification system
Most of the EoE cases (96%) received treatment with topical steroids, and post-treatment 
data were available for all 67 cases. The mean of the maximum eosinophil counts decreased 
from 150 eos/hpf at baseline to 50 eos/hpf after treatment (p < 0.001), and 38 cases (57%) 
had a histologic response as defined by <15 eos/hpf.
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The endoscopic findings significantly improved for EoE cases after treatment, as reflected in 
all individual and total EREFS scores, with the exception of strictures (Table 2). The total 
score decreased from 3.88 to 2.01, with the inflammatory score decreasing from 2.41 to 1.22 
and the fibrostenotic score decreasing from 1.46 to 0.89 (p < 0.001 for all). While these 
trends persisted for subjects after stratification by baseline esophageal dilation status, the 
improvement in all endoscopic features was more notable in EoE cases that did not require 
baseline dilation (Supplemental Table). While strictures did not resolve in the group 
undergoing dilation, the esophageal caliber did improve with this treatment (9mm vs 12mm; 
p = 0.04).
The decreases in EREFS scores were even more prominent when comparing histologic 
responders and non-responders, with all scores significantly improving in the histologic 
responders (Table 3). Non-responders had total, inflammatory, and fibrostenotic scores of 
3.24, 2.00, and 1.24, respectively, compared with 0.45, 0.63, and 1.08 for the responders (p 
< 0.001, p = 0.005, and p < 0.001, respectively). Mean post-treatment maximum eosinophil 
counts were 113 ± 98 eos/hpf in the non-responders compared with 3 ± 4 eos/hpf in the 
responders.
At baseline, the maximum eosinophil count among EoE cases was associated with the 
severity of the exudate score, but not with the other EREFS features (Figure 1A). For grade 
0, 1, and 2 exudates, the mean eosinophil counts were 118, 135, and 248 eos/hpf, 
respectively (p = 0.02). At follow-up, however, all EREFS findings were associated the 
post-treatment eosinophil count, with more severe findings associated with higher counts 
(Figure 1B).
Prediction of treatment response and optimization of EREFS scoring
On ROC analysis, baseline EREFS findings had a modest ability to predict histologic 
response to treatment. A model with all five components had an AUC of 0.730. The follow-
up EREFS findings, however, were more predictive of post-treatment histologic response. 
The model with all five components had an AUC of 0.880.
The iterative analysis investigating weighing the EREFS features differently showed that 
increasing the weight of the exudate, rings, and edema score modestly increased the 
predictive power when the change in eosinophil counts was treated continuously 
(Supplemental Figure 1A), and that increasing the weight of exudates and rings was 
beneficial with a threshold eosinophil count (< 15 eos/hpf) for response (Supplemental 
Figure 1B). We created a set of EREFS scores based on these varying weights and found 
that doubling the exudates, rings, and edema scores maximized the responsiveness of the 
total EREFS score (delta of 3.19, compared with a delta of 1.87 for the standard score; 
Supplemental Figure 2) while minimizing the complexity of the weighting system. 
However, these more responsive scores did not change the overall predictive ability as 
measured by the AUC.
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Discussion
It is only recently that the EREFS classification system has been proposed as a method for 
standardizing recognition and reporting of the main endoscopic features of EoE.9 While this 
system has been demonstrated to have good inter- and intra-observer agreement,9, 10 the 
diagnostic utility and responsiveness of the system are unknown. This prospective study, the 
first of its kind studying the EREFS system, aimed to address these knowledge gaps and 
there were several notable findings. First, the total EREFS score is highly predictive of EoE 
and potentially could have diagnostic utility. Second, the EREFS findings are highly 
responsive to treatment and therefore can be used as an outcome measure. Third, the initial 
scoring system is simple and appropriate for clinical use, though a weighed scoring system 
may be preferable for clinical trial outcomes to maximize responsiveness.
The characteristic endoscopic findings of EoE were noted in early reports of the disease,6 
and confirmed as more experience accumulated over the past two decades.20 However, 
endoscopic features were not universal and they have not been included in diagnostic 
guidelines.1, 2 This decision was supported by data showing that inter- and intra-observer 
agreement on endoscopic findings was fair,7 as well as by a meta-analysis that showed 
individual endoscopic findings were not sensitive or specific enough to support a diagnosis 
of EoE.8 However, in that study, a sub-analysis of prospective studies found that 93% of 
patients had at least one endoscopic finding, suggesting that carefully performed 
examinations by endoscopists familiar with the manifestations of EoE would likely be 
positive. One goal of the EREFS classification was to increase awareness and recognition of 
EoE endoscopic finding by creating an atlas; a second goal was to create a standardized 
reporting system for accurately tracking findings over time.9 That this system is helpful for 
increasing agreement of reported endoscopic findings has already been documented.10 
However, our study is the first to assess EREFS in cases and controls, the first to assess 
them prospectively, and the first to show that this system is responsive to treatment.
Our study confirms that the EREFS findings are highly predictive of EoE. With prospective 
upper endoscopic examination of patients prior to their diagnosis of EoE, we found that 
nearly all EoE patients (96%) had at least one endoscopic finding of the condition. Because 
these findings were much less common in non-EoE controls, the total EREFS score has 
diagnostic utility, with a score above 2 having good sensitivity and specificity. Moreover, 
the EREFS score was responsive to treatment; the scores decreased significantly in 
association with histologic improvement. This implies that the endoscopic features, as 
measured by the EREFS score, are a viable treatment outcome. It is notable that while 
exudates, rings, edema, and furrows improved with treatment, strictures did not. This is not 
unexpected as fibrostenotic changes of EoE12 have been shown to be treatment-resistant 
during an initial treatment period,22, 27, 28 though this is not universal.21 Two additional 
points are of interest in interpreting our findings. First, we found that with the exception of 
exudates, the baseline EREFS findings are not associated with pre-treatment eosinophil 
counts and have only a modest ability to predict histologic response. Second, the analysis of 
different weighting systems for creating an EREFS score showed that the initial grading 
classification proposed by Hirano et al9 is responsive and likely sufficient for routine use. 
However, if a greater change in score is desired in a clinical trial setting, doubling the 
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exudates, rings, and edema scores maximized the responsiveness of the total EREFS score 
while minimizing the complexity of the weighting system.
There are several limitations of this study. First, because it was conducted at a tertiary care 
center with the majority of assessments performed by endoscopists experienced in EoE, it is 
not known if the results could be generalized to all gastroenterologists. Future studies should 
examine the performance of EREFS in a community setting to confirm the utility there. 
Second, it included only an adult population. Therefore, it is unknown if our results can be 
applied to children, particularly because they tend not to have fibrostenotic manifestations.8 
It is, however, encouraging in this regard that the inflammatory component appeared to have 
the best discriminative capability between cases and controls. The majority of the subjects in 
our study were treated with topical steroids, with only a few treated with dietary elimination. 
However, there is little reason to think that the scoring system would be impacted by the 
type of treatment, as long as that treatment is successful. Additionally, because endoscopists 
were not blinded and were aware of the clinical history and cases status after treatment, we 
cannot eliminate the possibility that this introduced bias in their esophageal endoscopic 
examination. Finally, the score was optimized for histologic response, and this could have 
placed additional weight on the inflammatory features. While we did find that doubling the 
weight on the rings score increased the responsiveness, in the future differential weighting 
might be required if symptom outcomes are of primary importance.
This study also has a number of strengths. It was prospective and included a large number of 
both incident cases and controls. The baseline analysis of the cases and controls allowed us 
to study the diagnostic utility of EREFS, while the prospective cohort component allowed 
responsiveness assessment. Methodology was rigorous, with standardized data collection 
and treatment protocols, and careful patient retention, with no loss to follow-up. We were 
also able to stratify by baseline dilation status and perform an analysis to optimize scoring.
In conclusion, this prospective study found that the EREFS classification has diagnostic 
utility for EoE. Moreover, the score is responsive to treatment, decreasing significantly in 
histologic responders, and can be used as an outcome measure. In routine clinical practice, a 
score derived from simply summing the grades of endoscopic severity performs well. 
However, for research purposes or in clinical trials where a larger delta between pre- and 
post-treatment is desired, a scoring system with increased weights for exudates, rings, and 
edema may be preferable, though more prospective data would be needed to fully endorse 
this concept.
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Relationship between the maximum eosinophil count and grade of the EREFS features at 
baseline (A) and post-treatment (B). For the post-treatment cases, none had grade 3 rings.
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Table 1
Clinical, endoscopic, and histologic characteristics of the controls and EoE cases
Non-EoE controls (n = 144) EoE cases (n = 67) p*
Age at diagnosis (mean ± SD) 51.6 ± 13.5 38.0 ± 13.0 < 0.001
Male (n, %) 54 (38) 39 (58) 0.005
White (n, %) 118 (82) 63 (94) 0.02
Symptoms/EGD indication (n, %)
 Dysphagia 108 (75) 65 (97) < 0.001
 Heartburn 103 (72) 12 (18) < 0.001
 Abdominal pain 9 (6) 7 (10) 0.28
 Nausea/vomiting 12 (8) 1 (1) 0.05
Atopic disorders (n, %)
 Asthma 33 (23) 20 (30) 0.28
 Atopic dermatitis 10 (7) 5 (7) 0.89
 Allergic rhinitis/sinusitis 69 (48) 44 (66) 0.02
 Food allergies 21 (15) 30 (45) < 0.001
 Any atopic disease 83 (58) 50 (75) 0.02
EGD findings (n, %)
 Normal 23 (16) 3 (4) 0.02
 Rings 14 (10) 52 (78) < 0.001
 Stricture 26 (18) 16 (24) 0.32
 Narrowing 5 (3) 20 (30) < 0.001
 Furrows 9 (6) 60 (90) < 0.001
 Crêpe-paper 3 (2) 4 (6) 0.14
 White plaques/exudates 4 (3) 33 (49) < 0.001
 Decreased vascularity/edema 5 (3) 42 (63) < 0.001
 Dilation performed 44 (31) 21 (31) 0.91
Baseline maximum eosinophil count (mean ± SD) 2.5 ± 6.3 149.9 ± 124.2 < 0.001
Treatment (n, %)
 Topical steroids -- 65 (96) --
 Diet elimination -- 3 (4) --
Post-treatment eosinophil count (mean ± SD) -- 50.3 ± 84.2 --
 Response with < 15 eos/hpf (n, %) -- 38 (57) --
*
Proportions are compared with chi-square; means are compared with a two-sample t-test
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Table 3
EREFS post-treatment features and scores stratified by histologic response
EoE nonresponders (n =29) EoE responders (<15 eos/hpf) (n = 38) p*
EREFS findings (n, %) and scores (mean ±SD)
 Exudates
   0 17 (59) 34 (89) 0.013
   1 9 (31) 3 (8)
   2 3 (10) 1 (3)
  Score 0.51 ± 0.69 0.13 ± 0.41 0.006
 Rings
   0 12 (41) 19 (50) 0.06
   1 11 (38) 18 (47)
   2 6 (21) 1 (3)
   3 0 (0) 0 (0)
  Score 0.79 ± 0.77 0.53 ± 0.56 0.11
 Edema
   0 13 (45) 35 (92) < 0.001
   1 16 (55) 3 (8)
  Score 0.55 ± 0.51 0.08 ± 0.27 < 0.001
 Furrows
   0 6 (21) 29 (76) < 0.001
   1 19 (65) 9 (24)
   2 4 (14) 0 (0)
  Score 0.93 ± 0.59 0.24 ± 0.43 < 0.001
 Stricture
   0 16 (55) 34 (89) 0.001
   1 13 (45) 4 (11)
  Score 0.45 ± 51 0.11 ± 0.31 0.001
  Stricture size (mean mm ± SD) 13.1 ± 3.0 13.6 ± 3.5 0.75
 Inflammatory score (mean ± SD) 2.00 ± 1.34 0.45 ± 0.60 < 0.001
 Fibrostenotic score (mean ± SD) 1.24 ± 0.99 0.63 ± 0.71 0.005
 Total score (mean ± SD) 3.24 ± 1.79 1.08 ± 1.00 < 0.001
*
Proportions are compared with chi-square; means are compared with a two sample t-test
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